Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Acimtamig · AFM-13

Bispecific antibody · Immune activation, directed at CD30 (TNFRSF8) and CD16A (FCGR3A) · developed by Affimed GmbH

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Acimtamig?

Acimtamig is a tetravalent bispecific antibody that binds CD30 on tumor cells and CD16A on natural killer cells, cross-linking them to trigger NK cell activation and antibody-dependent cellular cytotoxicity. It is studied in relapsed or refractory Hodgkin lymphoma and peripheral T cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AFM-13
Drug type
Bispecific antibody
Targets
CD30 (TNFRSF8), CD16A (FCGR3A)
Mechanism
Immune activation, directed at CD30 (TNFRSF8) and CD16A (FCGR3A)
Pathways
ADCC, NK cell activation
Therapy area
Oncology
Developer
Affimed GmbH
In trials of
ARTV
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
ND470TT8Y3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05883449 Phase 2 Relapsed or Refractory Hodgkin Lymphoma Terminated ARTV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Peripheral T Cell LymphomaRelapsed or Refractory Hodgkin Lymphoma

Other drugs acting on TNFRSF8 / FCGR3A

GTB-5550 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.